Trulicity Market Size
| Study Period | 2021-2029 |
| Market Size (2024) | USD 8.60 Billion |
| Market Size (2029) | USD 14.20 Billion |
| CAGR (2024 - 2029) | 10.00 % |
| Fastest Growing Market | North America |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Trulicity Market Analysis
The Trulicity Market size is estimated at USD 8.60 billion in 2024, and is expected to reach USD 14.20 billion by 2029, growing at a CAGR of greater than 10% during the forecast period (2024-2029).
The Centers for Disease Control (CDC) determined that COVID-19 was a serious public health threat for people with serious chronic diseases, including diabetes. People with diabetes were more likely to experience complications when infected with the virus. As per the American Diabetes Association, people with diabetes, if uncontrolled, had worse outcomes if infected with a virus such as COVID-19. The International Diabetes Federation explained that when people with diabetes develop a viral infection, it can be harder to treat due to fluctuations in blood glucose levels and diabetes complications as the immune system is compromised, making it harder to fight the virus and likely leading to a longer recovery period.
Further, during the COVID-19 pandemic, many restrictions were imposed, putting people into lockdown, which led to contribution to obesity through unhealthy diets, physical inactivity, or highly sedentary behaviors. Further, these factors were associated with sustained weight gain and persisted even after lockdown restrictions were lifted. Weight management guidelines recommended a multi-component approach for weight loss in patients living with obesity and overweight. The use of anti-obesity medications was an effective option for weight control to improve the quality of life and prevent the progression of weight-related comorbidities.
Trulicity is an injectable diabetes medicine that helps control blood sugar levels. Trulicity is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is also used to help reduce the risk of serious heart problems such as heart attack or stroke in adults who have type-2 diabetes and heart disease. It is used for adults and children 10 years of age and older with type-2 diabetes, along with diet and exercise to improve blood sugar.
The World Health Assembly Resolution 2022 recommends the integration of prevention and treatment of diabetes into primary health services, the development of pathways for a substantial increase in access to insulin, the promotion of convergence and harmonization of regulatory requirements for diabetes medicines and technologies, and improved diabetes monitoring and surveillance. Furthermore, it involves the WHO to advise the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.
Major factors that are expected to boost the growth of the studied market in the forecast period are rising obesity and inactivity rates among people, which have resulted in an increase in the diabetes population over time, a rise in the sedentary lifestyle, improper dietary patterns, and the inherent history of diabetes disorders. In addition, rising investment in research and development, technological developments, and new product launches will further provide potential opportunities for the growth of glucagon-like peptide 1 (GLP-1) agonists such as Trulicity in the coming years.
Trulicity Market Trends
Rising obesity and diabetes prevalence globally
The diabetes population globally is expected to rise by 1.9% during the forecast period.
The major factors attributing to the growth of the market studied are an increase in obesity among people and a rising prevalence rate of type-2 diabetes and heart diseases. People with more fat in their bodies are highly likely to be affected by diabetes. For instance, as per the World Obesity Atlas 2023, the estimates for global levels of overweight and obesity (BMI ≥25kg/m²) suggest that over 4 billion people may be affected by 2035. The prevalence of obesity (BMI ≥30kg/m²) alone is anticipated to rise to 24% of the population over the same period, affecting nearly 2 billion adults, children, and adolescents by 2035.
Additionally, according to the World Health Organization (WHO) May 2022 report on the European region, in the WHO European Region, over 60% of adults and 29% of boys and 27% of girls who are children are overweight or obese and also, as per the same report, overweight and obesity rank fourth among the risk factors for non-communicable diseases in the region, after high blood pressure, unhealthy eating, and cigarette use. Furthermore, according to the latest International Diabetes Federation report, it is estimated that the number of adults in the age group of 20-79 years across the world is projected to increase to 643 million by 2030. Hence, owing to the high burden of obesity and the increasing prevalence of risk factors for obesity are expected to fuel the market growth over the forecast period.
North America held the highest market share in the current year
The North American region held the highest market share in the current year.
In the North American region, the prevalence of diabetes has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes owing to less physical activity, unhealthy food habits, and other lifestyle factors.
The American Diabetes Association (ADA), the Endocrine Society, the American College of Physicians, the American Academy of Paediatrics, the Society of General Internal Medicine, and the National Academy of Medicine published statements and issued calls to action to address social determinants of health at the individual, organizational, and policy levels. ADA also published a scientific review describing the associations between SDOH and diabetes risk and outcomes, focusing on socioeconomic status, health literacy, the food environment, food insecurity, and neighborhood and physical environments, among other topics.
The Centers for Disease Control and Prevention (CDC) National Diabetes Statistics Report 2022 estimated that more than 130 million adults are living with diabetes or prediabetes in the United States. Type-2 diabetes is more common, and diabetes is more consequential among communities of color, those who live in rural areas, and those with less education, lower incomes, and lower health literacy.
Therefore, the studied market is anticipated to grow over the analysis period due to rising prevalence and the factors above.
Trulicity Industry Overview
The Trulicity Market is consolidated with no generic products.
Trulicity Market Leaders
-
Eli Lilly
*Disclaimer: Major Players sorted in no particular order
Trulicity Market News
- November 2023: Eli Lilly New Zealand expected limited availability of the type-2 Diabetes (T2D) medication Trulicity (dulaglutide) due to global supply pressure. The company is focused on maintaining supplies of Trulicity in New Zealand for existing patients. The supply situation is expected to continue to remain dynamic until the end of 2024. During this time, patients in New Zealand may experience delays or interruptions in fulfilling their Trulicity prescriptions.
- July 2023: Eli Lilly has informed the Therapeutic Goods Administration (TGA) that the limited availability of Trulicity (dulaglutide) will be extended to 31 December 2024, in line with a similar notification for Ozempic (semaglutide).
Trulicity Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Drivers
- 4.3 Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
- 5.1 Trulicity
-
5.2 Geography
- 5.2.1 North America
- 5.2.1.1 United States
- 5.2.1.2 Canada
- 5.2.1.3 Rest of North America
- 5.2.2 Europe
- 5.2.2.1 Germany
- 5.2.2.2 Spain
- 5.2.2.3 Italy
- 5.2.2.4 France
- 5.2.2.5 United Kingdom
- 5.2.2.6 Russia
- 5.2.2.7 Rest of Europe
- 5.2.3 Asia-Pacific
- 5.2.3.1 Japan
- 5.2.3.2 China
- 5.2.3.3 Australia
- 5.2.3.4 India
- 5.2.3.5 South Korea
- 5.2.3.6 Malaysia
- 5.2.3.7 Indonesia
- 5.2.3.8 Thailand
- 5.2.3.9 Philippines
- 5.2.3.10 Vietnam
- 5.2.3.11 Rest of Asia-Pacific
- 5.2.4 Latin America
- 5.2.4.1 Brazil
- 5.2.4.2 Mexico
- 5.2.4.3 Rest of Latin America
- 5.2.5 Middle East and Africa
- 5.2.5.1 South Africa
- 5.2.5.2 Saudi Arabia
- 5.2.5.3 Oman
- 5.2.5.4 Egypt
- 5.2.5.5 Iran
- 5.2.5.6 Rest of Middle East and Africa
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes population
- 6.2 Type-2 Diabetes population
7. COMPETITIVE LANDSCAPE
- 7.1 Eli Lilly
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityTrulicity Industry Segmentation
Trulicity (Dulaglutide) is a medication used for the treatment of type-2 diabetes in combination with diet and exercise. The Trulicity market is segmented by Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America).
The report offers the value (in USD) and volume (in Units) for the above segments.
| Geography | North America | United States |
| Canada | ||
| Rest of North America | ||
| Geography | Europe | Germany |
| Spain | ||
| Italy | ||
| France | ||
| United Kingdom | ||
| Russia | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | Japan |
| China | ||
| Australia | ||
| India | ||
| South Korea | ||
| Malaysia | ||
| Indonesia | ||
| Thailand | ||
| Philippines | ||
| Vietnam | ||
| Rest of Asia-Pacific | ||
| Geography | Latin America | Brazil |
| Mexico | ||
| Rest of Latin America | ||
| Geography | Middle East and Africa | South Africa |
| Saudi Arabia | ||
| Oman | ||
| Egypt | ||
| Iran | ||
| Rest of Middle East and Africa |
Trulicity Market Research FAQs
How big is the Trulicity Market?
The Trulicity Market size is expected to reach USD 8.60 billion in 2024 and grow at a CAGR of greater than 10% to reach USD 14.20 billion by 2029.
What is the current Trulicity Market size?
In 2024, the Trulicity Market size is expected to reach USD 8.60 billion.
Who are the key players in Trulicity Market?
Eli Lilly are the major companies operating in the Trulicity Market.
Which is the fastest growing region in Trulicity Market?
North America is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Trulicity Market?
In 2024, the North America accounts for the largest market share in Trulicity Market.
What years does this Trulicity Market cover, and what was the market size in 2023?
In 2023, the Trulicity Market size was estimated at USD 7.74 billion. The report covers the Trulicity Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Trulicity Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Trulicity Industry Report
Statistics for the 2024 Trulicity market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Trulicity analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
